Skip to main content
Cardiolucent

Treatment

Cholesterol-Lowering Therapy (Statins, PCSK9 inhibitors)

Layered LDL-lowering therapy matched to risk, response, and tolerance.

Lowering LDL cholesterol is one of the most effective ways to reduce the risk of heart attack, stroke, and cardiovascular death — and the available toolkit has expanded well beyond statins alone. Modern lipid therapy includes high-intensity statins (rosuvastatin, atorvastatin), the cholesterol absorption inhibitor ezetimibe, PCSK9 inhibitors (alirocumab, evolocumab), bempedoic acid, and the small interfering RNA agent inclisiran. For elevated lipoprotein(a), icosapent ethyl for high triglycerides, and a growing pipeline of emerging therapies, the conversation has moved from "are you on a statin?" to "are you at goal?" Dr. Kedan personalizes the regimen based on your specific risk, baseline lipid profile, and tolerance.

What This Treatment Approach Includes

  • Advanced lipid panel including ApoB, lipoprotein(a), and direct LDL when relevant
  • Risk-based LDL target (under 70 mg/dL or under 55 mg/dL for very high risk)
  • High-intensity statin (rosuvastatin or atorvastatin) as foundation when tolerated
  • Layered addition of ezetimibe, PCSK9 inhibitor, bempedoic acid, or inclisiran if not at goal
  • Statin-intolerance protocol: rechallenge, alternate dosing, alternative agents
  • Triglyceride management with icosapent ethyl when appropriate
  • Periodic lipid panel, liver function, and adherence checks

How It Works

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, which upregulates LDL receptors and pulls more LDL out of circulation. Ezetimibe blocks intestinal cholesterol absorption. PCSK9 inhibitors block a protein that degrades LDL receptors — preserving more receptors and lowering LDL by an additional 50 to 60 percent on top of a statin. Bempedoic acid acts upstream in cholesterol synthesis; inclisiran is a long-acting injectable that silences PCSK9 production. The classes are complementary, which is why combinations often outperform maximum-dose monotherapy.

Who This Is For

  • Established cardiovascular disease (secondary prevention) — LDL target generally under 55 mg/dL
  • Diabetes with risk factors or end-organ disease
  • Familial hypercholesterolemia or other genetic lipid disorders
  • Elevated coronary calcium score with intermediate or high estimated risk
  • Elevated lipoprotein(a) with family history of premature cardiovascular disease
  • Primary prevention with high estimated 10-year cardiovascular risk
  • Statin-intolerant patients needing alternative or layered therapy

Monitoring and Follow-Up

A baseline lipid panel and liver function test are obtained before initiation, with repeat lipid panel typically 6 to 12 weeks after starting or adjusting therapy to confirm response and adherence. Once at goal, follow-up stretches to every 6 to 12 months. Liver function is rechecked if symptoms warrant. Muscle symptoms are evaluated systematically — most reported "statin intolerance" responds to dose adjustment, alternate-day dosing, or a different statin rather than abandoning the class. Same-day labs at office visits accelerate the titration cycle.

How Cardiolucent Manages This

Many patients are on submaximal lipid therapy, never reach LDL goal, and have never had an advanced lipid panel (ApoB or lipoprotein(a)) drawn. Dr. Kedan rebuilds the regimen using complete data, lays out a clear LDL target based on your risk, and layers therapy until you reach it. Extended visits make the statin-intolerance conversation thorough — rechallenges, alternate-day strategies, and add-on therapy are explored before assuming a class can't be used. Same-day labs at office visits keep the titration tight.

Common Questions

Frequently Asked Questions

What is my LDL goal?
It depends on your overall cardiovascular risk. Patients with established cardiovascular disease typically target LDL under 70 mg/dL, with very high-risk patients (recurrent events, diabetes with end-organ disease, familial hypercholesterolemia) targeted to under 55 mg/dL. Primary prevention targets vary by risk category. Dr. Kedan sets the goal individually based on your full picture.
Are statins safe?
Statins have one of the most extensive safety records in modern medicine, with decades of trials and real-world data. Muscle symptoms are the most commonly reported side effect, but blinded trials show that the rate of true statin-attributable muscle pain is much lower than patient reporting suggests. Liver enzyme elevation is uncommon and usually reversible. Most patients tolerate statins well when matched to the right agent and dose.
What if I cannot tolerate a statin?
Statin intolerance is approached systematically — usually starting with a rechallenge of the same or an alternative statin at a lower or alternate-day dose, then layering ezetimibe, bempedoic acid, or PCSK9 inhibitor / inclisiran as needed. Most patients labeled as statin-intolerant can ultimately tolerate some statin therapy with the right approach, and those who truly cannot have effective non-statin options.
What are PCSK9 inhibitors?
PCSK9 inhibitors (alirocumab and evolocumab) are injectable monoclonal antibodies that block the PCSK9 protein, allowing more LDL receptors to recycle to the cell surface and pulling more LDL out of the blood. On top of a statin, they reduce LDL by an additional 50 to 60 percent and have been shown to reduce cardiovascular events in patients with established disease.
What is inclisiran, and how is it different?
Inclisiran is a small interfering RNA agent that silences the production of PCSK9 in the liver. It is dosed twice yearly after an initial loading regimen, which is a substantial adherence advantage. LDL lowering is similar to the antibody-based PCSK9 inhibitors. It is an appropriate option for patients on maximal oral therapy still above goal.
What about lipoprotein(a)?
Lipoprotein(a) is a genetically determined lipid particle that independently raises cardiovascular risk and is not meaningfully changed by statins. PCSK9 inhibitors lower it modestly; targeted lp(a)-lowering therapies are in late-stage clinical development. For patients with elevated lp(a), aggressive lowering of standard LDL becomes even more important. Dr. Kedan checks lp(a) at least once in most adults.
What are the side effects of these medications?
Statins can cause muscle aches, occasional liver enzyme elevation, and a small increase in blood glucose. Ezetimibe is generally well tolerated. PCSK9 inhibitors can cause mild injection-site reactions. Bempedoic acid can cause uric acid elevation. Specific profiles are reviewed before starting any agent.
How long will I be on cholesterol therapy?
Indefinitely in most cases, because LDL rises again when therapy is stopped and the underlying risk does not resolve. The conversation evolves as risk factors and life stage change, but lifelong therapy is the norm for secondary prevention and most high-risk primary prevention.
How important is diet relative to medication?
Both matter. A Mediterranean or DASH dietary pattern lowers LDL modestly on its own and supports overall cardiovascular health regardless of medication. However, dietary change rarely achieves the LDL reductions of pharmacotherapy in patients with established disease or genetic dyslipidemia. Dr. Kedan integrates both rather than pitting them against each other.
How do I start lipid therapy with Dr. Kedan?
Schedule a consultation at the Beverly Hills office. Bring prior lipid panels, family history, and a current medication list. Cardiolucent is a concierge practice and does not bill Medicare or insurance, though a detailed superbill is provided for out-of-network reimbursement. Call (310) 304-5555 or use the contact form.

Explore

Related Treatments

Aiming for the right LDL target?

Discuss this treatment with Dr. Kedan in Beverly Hills.
Schedule an Appointment

Medical Disclaimer

The information on this site is for general educational purposes only and is not medical advice, diagnosis, or treatment. Reading this site does not create a doctor–patient relationship. Always consult a qualified healthcare professional for personal guidance. If this is an emergency, call 911. Mentions of medications, devices, or procedures are informational and not endorsements. Full medical disclaimer.

†Some listed indications involve investigational/off-label use. Learn more.